Innovations

Omicron variant BQ.1.1 found to be resistant to all monoclonal antibody treatments

0
Specialist researcher holding microscope slide analyzing blood sample working at coronavirus vaccine development during virus examination in microbiology hospital laboratory. Biochemistry experiment

A combined team of researchers from Leibniz Institute for Primate Research and Friedrich-Alexander University of Erlangen-Nürnberg, both in Germany, has found that the SARS-CoV-2 omicron variant BQ.1.1 is resistant to all known monoclonal antibody treatments. In their study, published in The Lancet—Infectious Diseases, the group tested a host of omicron sublineages against all known antibody treatments.

Advancing the state of the art in neutralizing stronger COVID-19 variants

Previous article

Survey: Two-thirds of European dietitians believe drinking coffee in moderation has clear health benefits

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations